Mpox is a contagious viral disease transmitted by direct contact with infected body fluids, skin lesions, or contaminated objects. Mpox causes fever, headache, muscle pain, rash and blisters on the skin and mucous membranes. Mpox was first identified in 2009, and sporadic outbreaks have occurred in several African countries, Europe, the US and Asia. In August 2024, the WHO upgraded mpox to a public health emergency of international concern given the extent of the current outbreak in Africa. It is expected there may be some additional limited regional outbreaks outside Africa as well. Given how mpox is spread, the risk of contracting mpox is low in a regular workplace environment. There is a mpox vaccine available, and ring vaccination of close contacts has proved helpful in eliminating outbreaks from person-to-person transmission.
As of August 2024, no specific precautionary measures are suggested for employers by public health or occupational health and safety groups, since the risk of spread in the workplace is low. There are two vaccinations available for mpox, but availability is limited and only suggested for individuals who are age 18 or older and either have a known exposure to mpox or participate in activities considered high risk.
Employees with questions about eligibility or availability should reach out to their medical provider.
The CDC has a suggested list of steps individuals can take to protect themselves from mpox.